Nivolumab in the treatment of malignant melanoma: review of the literature

References

• DeeksEDNivolumab: a review of its use in patients with malignant melanomaDrugs201474111233123925022950
   PubMed Web of Science ®Google Scholar
• OkuraRYoshiokaHYoshiokaMHiromasaKNishioDNakamuraMExpression of AID in malignant melanoma with BRAF(V600E) mutationExp Dermatol201423534734824684646
   PubMed Web of Science ®Google Scholar
• TopalianSLWeinerGJPardollDMCancer immunotherapy comes of ageJ Clin Oncol201129364828483622042955
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• OkazakiTChikumaSIwaiYFagarasanSHonjoTA rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNat Immunol201314121212121824240160
   PubMed Web of Science ®Google Scholar
• LuJLee-GabelLNadeauMCFerenczTMSoefjeSAClinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapyJ Oncol Pharm Pract Epub201469
   PubMed Web of Science ®Google Scholar
• IshidaYAgataYShibaharaKHonjoTInduced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J19921111388738951396582
   PubMed Web of Science ®Google Scholar
• OkazakiTHonjoTPD-1 and PD-1 ligands: from discovery to clinical applicationInt Immunol200719781382417606980
   PubMed Web of Science ®Google Scholar
• OkazakiTMaedaANishimuraHKurosakiTHonjoTPD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosineProc Natl Acad Sci U S A20019824138661387111698646
   PubMed Web of Science ®Google Scholar
• NishimuraHMinatoNNakanoTHonjoTImmunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responsesInt Immunol19981010156315729796923
   PubMed Web of Science ®Google Scholar
• NishimuraHNoseMHiaiHMinatoNHonjoTDevelopment of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptorImmunity199911214115110485649
   PubMed Web of Science ®Google Scholar
• NishimuraHOkazakiTTanakaYAutoimmune dilated cardiomyopathy in PD-1 receptor-deficient miceScience2001291550231932211209085
   PubMed Web of Science ®Google Scholar
• ThompsonRHGillettMDChevilleJCCostimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetProc Natl Acad Sci U S A200410149171741717915569934
   PubMed Web of Science ®Google Scholar
• OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
   PubMed Web of Science ®Google Scholar
• WuCZhuYJiangJZhaoJZhangXGXuNImmunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significanceActa Histochem20061081192416530813
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIwasakiMProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProc Natl Acad Sci U S A200710493360336517360651
   PubMed Web of Science ®Google Scholar
• NakanishiJWadaYMatsumotoKAzumaMKikuchiKUedaSOverexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancersCancer Immunol Immunother20075681173118217186290
   PubMed Web of Science ®Google Scholar
• NomiTShoMAkahoriTClinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancerClin Cancer Res20071372151215717404099
   PubMed Web of Science ®Google Scholar
• HinoRKabashimaKKatoYTumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanomaCancer201011671757176620143437
   PubMed Web of Science ®Google Scholar
• MassiDBrusaDMerelliBPD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristicsAnn Oncol201425122433244225223485
   PubMed Web of Science ®Google Scholar
• ThompsonRHDongHLohseCMPD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinomaClin Cancer Res20071361757176117363529
   PubMed Web of Science ®Google Scholar
• MuenstSSoysalSDGaoFObermannECOertliDGillandersWEThe presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancerBreast Cancer Res Treat2013139366767623756627
   PubMed Web of Science ®Google Scholar
• IwaiYTerawakiSHonjoTPD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cellsInt Immunol200517213314415611321
   PubMed Web of Science ®Google Scholar
• IwaiYIshidaMTanakaYOkazakiTHonjoTMinatoNInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProc Natl Acad Sci U S A20029919122931229712218188
   PubMed Web of Science ®Google Scholar
• WongRMScotlandRRLauRLProgrammed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLsInt Immunol200719101223123417898045
   PubMed Web of Science ®Google Scholar
• O’Sullivan CoyneGMadanRAGulleyJLNivolumab: promising survival signal coupled with limited toxicity raises expectationsJ Clin Oncol2014321098698824590655
   PubMed Web of Science ®Google Scholar
• McDermottDFAtkinsMBPD-1 as a potential target in cancer therapyCancer Med20132566267324403232
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• WeberJSKudchadkarRRYuBSafety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanomaJ Clin Oncol201331344311431824145345
   PubMed Web of Science ®Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar
• GangadharTCSalamaAKSClinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor typesOnco Targets Ther2015892993725960664
   PubMed Web of Science ®Google Scholar